Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Lyra Therapeutics, Inc. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
LYRA
Nasdaq
2830
lyratherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Lyra Therapeutics, Inc.
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know
- Jan 9th, 2025 5:00 pm
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Nov 14th, 2024 12:06 pm
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
- Nov 12th, 2024 10:15 pm
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov 12th, 2024 9:01 pm
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis
- Oct 15th, 2024 11:00 am
Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings
- Sep 27th, 2024 11:00 am
Lyra Therapeutics Insiders Still US$66k Away From Original Investment Value
- Aug 22nd, 2024 10:45 am
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
- Aug 14th, 2024 9:30 pm
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Aug 14th, 2024 8:01 pm
Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1?
- Jul 15th, 2024 3:35 pm
Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
- May 21st, 2024 1:14 pm
Target upgraded, CVS downgraded: Wall Street's top analyst calls
- May 7th, 2024 1:54 pm
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
- May 6th, 2024 11:59 am
Lyra Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
- May 2nd, 2024 11:30 am
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
- Apr 30th, 2024 9:30 pm
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Apr 30th, 2024 8:04 pm
Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 26th, 2024 8:51 pm
Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
- Mar 28th, 2024 11:08 am
Private equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as well
- Mar 26th, 2024 11:27 am
Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why
- Mar 25th, 2024 12:50 pm
Scroll